Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of ...

Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform ...

The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...

Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed ...